XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.3
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Disaggregation of Revenue
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Revenue related to Genentech agreement:
Recognition of license revenue$48,679 $— $48,679 $— 
Research services547 — 547 — 
Total$49,226 $— $49,226 $— 
Revenues recognized under these agreements were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$— $5,388 $— $17,938 
Research services variable consideration— 108 — 1,097 
Total$— $5,496 $— $19,035 
Revenue related to Novartis agreement:
Recognition of upfront license fee$— $— $— $9,568 
Research services— — — 2,611 
Total$— $— $— $12,179 
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$— $— $— $132,165 
Cost-sharing payments for research services, net variable consideration— — — 2,684 
Total$— $— $— $134,849 
Revenue from other license agreements$186 $3,902 $1,023 $8,127 
Total revenue$186 $9,398 $1,023 $174,190